Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASI Pharmaceuticals, Inc.CASI · Entity 123920 | Director | May 25, 2022 | May 26, 2022 |
| Scilex Holding CoSCLX · Entity 7345 | Director | October 08, 2025 | October 09, 2025 |
| Semnur Pharmaceuticals, Inc.SMNR · Entity 6623 | Director | September 22, 2025 | September 23, 2025 |
| Sorrento Therapeutics, Inc.SRNE · Entity 109201 | Director | August 30, 2021 | August 30, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASI Pharmaceuticals, Inc.
Report date May 25, 2022 · Filed May 26, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.47 · Expires 2032-05-25 | Direct | 388,387 |
Reported balance
After 2022-05-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-25 · Grant · Acquired 388,387 · Balance 388,387 F1: Stock option award will vest ratably quarterly to the end of the year. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option award will vest ratably quarterly to the end of the year.
Scilex Holding Co
Report date October 08, 2025 · Filed October 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.58 · Expires 2035-10-08 | Direct | 20,000 |
Reported balance
After 2025-10-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-08 · Grant · Acquired 20,000 · Balance 20,000 F1: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Semnur Pharmaceuticals, Inc.
Report date September 22, 2025 · Filed September 23, 2025
This filing explicitly reported no securities owned.
Sorrento Therapeutics, Inc.
Report date August 30, 2021 · Filed August 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.86 · Expires 2031-08-30 | Direct | 250,000 |
Reported balance
After 2021-08-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-08-30 · Grant · Acquired 250,000 · Balance 250,000 F1: 1/48th of the original number of shares subject to this option shall vest and become exercisable on September 30, 2021, and 1/48th of the original number of shares subject to the option shall vest following each one month of service thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the original number of shares subject to this option shall vest and become exercisable on September 30, 2021, and 1/48th of the original number of shares subject to the option shall vest following each one month of service thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 08, 2025 Filed Oct 9, 2025 08:47 UTC | Scilex Holding Co SCLX · Entity 7345 | GrantNonstatutory Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.58 | $0.00 |
DisclosureSEC source: 0001193125-25-235248 · ownership.xml · derivative · entry 1 Wu Yue Alexander · CIK 0001682419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-10-08 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 17:13 UTC | Scilex Holding Co SCLX · Entity 7345 | GrantNonstatutory Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000950170-24-137369 · ownership.xml · derivative · entry 1 Wu Yue Alexander · CIK 0001682419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-12-16 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 09:14 UTC | Scilex Holding Co SCLX · Entity 7345 | PurchaseCommon Stock | 20,000 | $0.95 | $18,992.00 |
DisclosureSEC source: 0000950170-24-115452 · ownership.xml · nonDerivative · entry 1 Wu Yue Alexander · CIK 0001682419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · kind: Open market purchase by the reporting person of 20,000 shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock reported represents an aggregate number of shares purchased in multiple open market transactions over a range of sales prices. F2 · price: Reflects the weighted average price of the shares of Common Stock purchased on the open market in multiple transactions on October 17, 2024 at prices ranging from $0.9479 to $0.9497 per share, inclusive. The amount reflected has been rounded to four decimal points. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of such shares of Common Stock purchased at each separate price within such range. Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 18:07 UTC | Scilex Holding Co SCLX · Entity 7345 | Exercise / conversionNonstatutory Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0000950170-24-075773 · ownership.xml · derivative · entry 2 Wu Yue Alexander · CIK 0001682419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,000 Underlying: Common Stock · 5,000 shares Expires 2033-10-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48th of the number of shares subject to the option vested and shall vest on a monthly basis following the grant date, which was October 4, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 18:07 UTC | Scilex Holding Co SCLX · Entity 7345 | Exercise / conversionCommon Stock | 5,000 | $1.41 | $7,050.00 |
DisclosureSEC source: 0000950170-24-075773 · ownership.xml · nonDerivative · entry 1 Wu Yue Alexander · CIK 0001682419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: 1/48th of the number of shares subject to the option vested and shall vest on a monthly basis following the grant date, which was October 4, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| October 04, 2023 Filed Oct 5, 2023 21:26 UTC | Scilex Holding Co SCLX · Entity 7345 | GrantNonstatutory Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0000950170-23-052256 · ownership.xml · derivative · entry 1 Wu Yue Alexander · CIK 0001682419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-10-04 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| May 25, 2022 Filed May 26, 2022 16:13 UTC | CASI Pharmaceuticals, Inc. CASI · Entity 123920 | GrantStock Option (Right to Buy) · Derivative | 388,387 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001104659-22-065267 · tm2214964d3_4.xml · derivative · entry 1 Wu Yue Alexander · CIK 0001682419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,387 Underlying: Common Stock · 388,387 shares Expires 2032-05-25 F1 · derivative.exercise_date: Stock option award will vest ratably quarterly to the end of the year. Read SEC document |
| August 30, 2021 Filed Aug 30, 2021 20:16 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock option (right to buy) · Derivative | 250,000 | $0.00 Strike: $8.86 | $0.00 |
DisclosureSEC source: 0001209191-21-053986 · doc4.xml · derivative · entry 1 Wu Yue Alexander · CIK 0001682419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-08-30 F1 · derivative.exercise_date: 1/48th of the original number of shares subject to this option shall vest and become exercisable on September 30, 2021, and 1/48th of the original number of shares subject to the option shall vest following each one month of service thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 16:02 UTC | CASI Pharmaceuticals, Inc. CASI · Entity 123920 | GrantStock Option (Right to Buy) · Derivative | 110,459 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001104659-21-081995 · tm2119809d5_4.xml · derivative · entry 1 Wu Yue Alexander · CIK 0001682419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,459 Underlying: Common Stock · 110,459 shares Expires 2031-06-15 F1 · date: Stock option award will vest ratably quarterly to the end of the year. F1 · derivative.exercise_date: Stock option award will vest ratably quarterly to the end of the year. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 06:04 UTC | CASI Pharmaceuticals, Inc. CASI · Entity 123920 | GrantStock Option (Right to Buy) · Derivative | 68,800 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001104659-20-074352 · tm2022841d3_form4.xml · derivative · entry 1 Wu Yue Alexander · CIK 0001682419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,800 Underlying: Common Stock · 68,800 shares Expires 2030-06-16 F1 · derivative.exercise_date: Stock option award will vest ratably quarterly to the end of the year. Read SEC document |
| June 15, 2020 Filed Jun 15, 2020 18:09 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0000850261-20-000042 · wf-form4_159225892982664.xml · derivative · entry 1 Wu Yue Alexander · CIK 0001682419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: 1/12th of the original number of shares subject to this option shall vest and become exercisable on July 15, 2020, and 1/12th of the original number of shares subject to the option shall vest following each one month of service thereafter, subject to the Reporting Person's continued service on the Issuer's board of directors on each such date. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 17:01 UTC | CASI Pharmaceuticals, Inc. CASI · Entity 123920 | GrantStock Option (Right to Buy) · Derivative | 57,885 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0001144204-19-031920 · tv524058_4.xml · derivative · entry 1 Wu Yue Alexander · CIK 0001682419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,885 Underlying: Common Stock · 57,885 shares Expires 2029-06-20 F1 · date: Stock option award will vest ratably quarterly to the end of the year. F1 · derivative.exercise_date: Stock option award will vest ratably quarterly to the end of the year. Read SEC document |
| April 19, 2019 Filed Apr 23, 2019 21:00 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 70,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0000850261-19-000011 · wf-form4_155606760258733.xml · derivative · entry 1 Wu Yue Alexander · CIK 0001682419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-04-19 F1 · derivative.exercise_date: 1/12 of the original number of shares subject to this option shall vest and become exercisable on May 14, 2019 and following each one month of service thereafter, subject to the Reporting Person's continued service on the Issuer's board of directors on each such date. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 19:48 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 35,000 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0000850261-18-000045 · wf-form4_154336611152477.xml · derivative · entry 1 Wu Yue Alexander · CIK 0001682419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-11-26 F1 · derivative.exercise_date: 1/12 of the original number of shares subject to this option shall vest and become exercisable following each one month of service thereafter, subject to the Reporting Person's continued service on the Issuer's board of directors on each such date. Read SEC document |
| September 15, 2017 Filed Sep 15, 2017 21:44 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 35,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001144204-17-048357 · v475323_4.xml · derivative · entry 1 Wu Yue Alexander · CIK 0001682419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-09-15 F1 · derivative.exercise_date: 1/12 of the original number of shares subject to this option shall vest and become exercisable following each one month of service thereafter, subject to the reporting person's continued service on the issuer's board of directors on each such date. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 06:20 UTC Amendment | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 35,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001144204-17-048378 · v475339_4a.xml · derivative · entry 1 Wu Yue Alexander · CIK 0001682419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-09-15 F1 · derivative.exercise_price: This amended report on Form 4 is being filed to amend the Form 4 filed by the reporting person on September 15, 2017 to correct the exercise price, which was inadvertently reported as $1.75. F2 · derivative.exercise_date: 1/12 of the original number of shares subject to this option shall vest and become exercisable following each one month of service thereafter, subject to the reporting person's continued service on the issuer's board of directors on each such date. Read SEC document |
| February 03, 2017 Filed Feb 3, 2017 19:51 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | PurchaseCommon Stock | 5,000 | $5.15 | $25,750.00 |
DisclosureSEC source: 0000899243-17-002791 · doc4.xml · nonDerivative · entry 1 Wu Yue Alexander · CIK 0001682419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.